<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wiki.tiffa.net/w/index.php?action=history&amp;feed=atom&amp;title=Translations%3AAngiotensin_II_receptor_blocker%2F33%2Fen</id>
	<title>Translations:Angiotensin II receptor blocker/33/en - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wiki.tiffa.net/w/index.php?action=history&amp;feed=atom&amp;title=Translations%3AAngiotensin_II_receptor_blocker%2F33%2Fen"/>
	<link rel="alternate" type="text/html" href="https://wiki.tiffa.net/w/index.php?title=Translations:Angiotensin_II_receptor_blocker/33/en&amp;action=history"/>
	<updated>2026-05-10T15:52:49Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.43.0</generator>
	<entry>
		<id>https://wiki.tiffa.net/w/index.php?title=Translations:Angiotensin_II_receptor_blocker/33/en&amp;diff=131265&amp;oldid=prev</id>
		<title>FuzzyBot: Importing a new version from external source</title>
		<link rel="alternate" type="text/html" href="https://wiki.tiffa.net/w/index.php?title=Translations:Angiotensin_II_receptor_blocker/33/en&amp;diff=131265&amp;oldid=prev"/>
		<updated>2024-03-25T09:03:20Z</updated>

		<summary type="html">&lt;p&gt;Importing a new version from external source&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;|-&lt;br /&gt;
| [[Valsartan]]&lt;br /&gt;
| Diovan&lt;br /&gt;
| 6&lt;br /&gt;
| 2–4 hrs&lt;br /&gt;
| 95%&lt;br /&gt;
| 25%&lt;br /&gt;
| 30/70%&lt;br /&gt;
| Yes&lt;br /&gt;
| 80–320&lt;br /&gt;
| Substrates: [[Multidrug resistance-associated protein 2|MRP2]] and [[OATP1B1|OATP1B1/SLCO1B1]]&lt;br /&gt;
|-&lt;br /&gt;
| [[Irbesartan]]&lt;br /&gt;
| Avapro&lt;br /&gt;
| 11–15&lt;br /&gt;
| 1.5–2 hrs&lt;br /&gt;
| 90–95%&lt;br /&gt;
| 70%&lt;br /&gt;
| 20/80%&lt;br /&gt;
| No&lt;br /&gt;
| 150–300&lt;br /&gt;
| Minor substrates of [[CYP2C9]]&lt;br /&gt;
|-&lt;br /&gt;
| [[Telmisartan]]&lt;br /&gt;
| Micardis&lt;br /&gt;
| 24&lt;br /&gt;
| 0.5–1 hr &lt;br /&gt;
| &amp;gt;99%&lt;br /&gt;
| 42–58%&lt;br /&gt;
| 1/99%&lt;br /&gt;
| No&lt;br /&gt;
| 40–80&lt;br /&gt;
| None known; &amp;gt;97% via biliary excretion&lt;br /&gt;
|-&lt;br /&gt;
| [[Eprosartan]]&lt;br /&gt;
| Teveten&lt;br /&gt;
| 5&lt;br /&gt;
| 1–2 hrs &lt;br /&gt;
| 98%&lt;br /&gt;
| 13%&lt;br /&gt;
| 30/70%&lt;br /&gt;
| No&lt;br /&gt;
| 400–800&lt;br /&gt;
| None known; &amp;gt;90% via renal and biliary excretion&lt;br /&gt;
|-&lt;br /&gt;
| [[Olmesartan]]&lt;br /&gt;
| Benicar/Olmetec&lt;br /&gt;
| 14–16&lt;br /&gt;
| 1–2 hrs &lt;br /&gt;
| &amp;gt;99%&lt;br /&gt;
| 29%&lt;br /&gt;
| 40/60%&lt;br /&gt;
| No&lt;br /&gt;
| 10–40&lt;br /&gt;
| Substrates of [[OATP1B1|OATP1B1/SLCO1B1]]&lt;br /&gt;
|-&lt;br /&gt;
| [[Azilsartan]]&lt;br /&gt;
| Edarbi&lt;br /&gt;
| 11&lt;br /&gt;
| 1.5–3 hrs &lt;br /&gt;
| &amp;gt;99%&lt;br /&gt;
| 60%&lt;br /&gt;
| 55/42%&lt;br /&gt;
| No&lt;br /&gt;
| 40–80&lt;br /&gt;
| Minor substrates of CYP2C9 &lt;br /&gt;
|-&lt;br /&gt;
| [[Fimasartan]]&lt;br /&gt;
| Kanarb&lt;br /&gt;
| 7–11&lt;br /&gt;
| 0.5–3 hrs after dosing.&lt;br /&gt;
| &amp;gt;97%&lt;br /&gt;
| 30–40%&lt;br /&gt;
| –&lt;br /&gt;
| –&lt;br /&gt;
| 30–120&lt;br /&gt;
| None known; primarily biliary excretion &lt;br /&gt;
|-&lt;br /&gt;
! Drug&lt;br /&gt;
! Trade name&lt;br /&gt;
! [[Biological half-life]] [hrs]&lt;br /&gt;
! [[Cmax_(pharmacology)|Peak plasma concentration [Tmax] ]]&lt;br /&gt;
! [[Protein binding]] [%]&lt;br /&gt;
! [[Bioavailability]] [%]&lt;br /&gt;
! Renal/hepatic [[Clearance (medicine)|clearance]] [%]&lt;br /&gt;
! Food effect&lt;br /&gt;
! Daily dosage [mg]&lt;br /&gt;
! [[Metabolism]]/[[Transport protein|transporter]]&lt;br /&gt;
|}&lt;/div&gt;</summary>
		<author><name>FuzzyBot</name></author>
	</entry>
</feed>